Scilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to Severe Acute Lower Back Pain (LBP)
Scilex Holding Company announced completion of its SP-103 Phase 2 study to evaluate the safety…
How to Repair Corrupt Exchange Databases Safely and Minimize Downtime
Veea Announces the VeeaONE Distributed Intelligence Platform, Enabling Cybersecure Sovereign Data Fabrics and Enterprise AI Grids for Physical AI